ATRX and central nervous system cancer: These results indicate that Atrx deficiency abnormally alters H3.3 composition at vacant Atrx binding sites, which in turn mediates, at least in part, shifts in chromatin accessibility and gene expression driving glioma-relevant phenotypes.